Showing posts with label BIOCON APPROACHES USFDA FOR APPROVAL. Show all posts
Showing posts with label BIOCON APPROACHES USFDA FOR APPROVAL. Show all posts

Wednesday, November 9, 2016

BIOCON APPROACHES USFDA FOR APPROVAL

Biocon and its partner Mylan have submitted an application for one of their product - biosimilar trastuzumab, to the USFDA.

Biocon says that this product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast and gastric cancers.